Cue Health, Fresenius Kidney Care partner on COVID-19 tests

2021 08 18 22 53 0531 Covid 19 Self Swab Test 400

Cue Health announced on Wednesday it has partnered with Fresenius Kidney Care to provide immunocompromised patients and their clinical care teams with COVID-19 self-tests.

Fresenius plans on using the Cue Health Monitoring System and the Cue COVID-19 test in two states and three territories -- Hawaii, Alaska, Puerto Rico, Guam, and Saipan -- to screen employees and provide early testing for vulnerable patients.

"This collaboration with Cue will help us provide patients with greater access to high-quality timely diagnosis and care in our effort to improve health outcomes while lowering costs," Ines Dahne-Steuber, president of Spectra Laboratories, a Fresenius Medical Care company, said in a statement.

Cue's test, which may be performed either at a center or at home, uses molecular nucleic acid amplification technology (NAAT) to gather and send results to a mobile device. It can be used on adults and children ages two years and older. Additionally, it can detect SARS-CoV-2 and its variants, including Omicron, BA.4, and BA.5.

Page 1 of 27
Next Page